Parabilis Medicines, Inc. (PBLS) Cash Flow Statement

Cash Flow Overview

Change in Cash

$1,059,349K

Free Cash flow

-$53,807K

Unit: Thousand (K) dollars

Positive Cash Flow Breakdown

Negative Cash Flow Breakdown

Cash Flow

2026-06-30

Net loss

-97,779

Depreciation and amortization

1,199

Accretion of discounts on marketable securities

208

Stock-based compensation expense

4,938

Non-cash interest expense

133

Non-cash lease expense

3,353

Change in fair value of simple agreement for future equity

5,556

Rent receivable - related party

Due from related party

Prepaid expenses and other assets

5,364

Operating lease liabilities

-3,510

Deferred revenue

41,519

Accounts payable, accrued expenses and other liabilities

-2,659

Net cash used in operating activities

-52,822

Purchases of marketable securities

33,447

Proceeds from maturities of marketable securities

Purchases of property and equipment

985

Net cash (used in) provided by investing activities

-34,432

Proceeds from issuance of convertible preferred stock-Series EConvertible Preferred Stock

Proceeds from issuance of convertible preferred stock-Series FConvertible Preferred Stock

305,249

Payments of convertible preferred stock issuance costs

680

Proceeds from issuance of simple agreement for future equity

50,000

Proceeds from initial public offering, net of underwriting discounts and commissions

718,240

Payments of initial public offering costs

2,499

Proceeds from concurrent private placement of common stock

83,333

Principal payments on finance leases

311

Principal payments on debt

7,500

Proceeds from exercise of stock options

771

Net cash provided by financing activities

1,146,603

Increase in cash, cash equivalents and restricted cash

1,059,349

Cash, cash equivalents and restricted cash at beginning of period

30,566

Cash, cash equivalents and restricted cash at end of period

1,089,915

Time Plot

Show the time plot by selecting a row from the table.